Title:Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Volume: 23
Issue: 7
Author(s): Ekaterina A. Ivanova, Veronika A. Myasoedova*, Alexandra A. Melnichenko and Alexander N. Orekhov
Affiliation:
- Unit of Atherosclerosis Prevention, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138, Milan,Italy
Keywords:
Peroxisome proliferation-activated receptor gamma (PPARγ), cardiovascular disorders, cardiovascular surgery,
atherosclerosis.
Abstract: Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that
mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the
PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three isoforms have therapeutic potential for treatment of
cardiovascular disorders, and PPAR agonists are currently being actively studied in pre-clinical and clinical trials.
PPAR γ agonists, main tissue expressing isoform, have potential to influence on inflammation processes, reduce
oxidative stress, improve endothelial function and plays an important role in lipid metabolism. PPAR-γ agonists
are used as insulin sensitizers for treatment of diabetes; however, there is accumulating evidence that their clinical
application can be broadened. The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of
various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical
interventions. In this Review we will discuss the implication of PPAR-γ in the cardiovascular system and
potential role of PPAR-γ agonists in treatment of conditions associated with high cardiovascular risks.
